Upk2 Antibody

What is uroplakin 2 (UPK2) and why is it significant for bladder research?

Uroplakin 2 (UPK2) is a member of the uroplakin family of integral membrane proteins specifically expressed in the urothelium of the bladder. Also known as UP2, UPII, and uroplakin II, this protein has a molecular mass of approximately 19.4 kilodaltons in humans . UPK2 plays a crucial role in maintaining the barrier function of bladder epithelium, making it an important target for studying various bladder disorders including interstitial cystitis and bladder cancer. The highly specific expression pattern of UPK2 in bladder tissue makes it an excellent biomarker for both diagnostic applications and for targeting bladder-specific processes .

How conserved is UPK2 across different species?

UPK2 demonstrates significant evolutionary conservation across mammalian species. Based on gene sequence analysis, orthologs have been identified in various species including canine, porcine, monkey, mouse, and rat models . This conservation makes UPK2 antibodies potentially cross-reactive across species, which is valuable for comparative studies. When designing experiments, researchers should consider that while the core functional domains may be conserved, species-specific variations might affect antibody binding affinity and specificity when working with animal models.

What are the most effective applications for UPK2 antibodies in research?

UPK2 antibodies demonstrate utility across multiple experimental techniques. Based on commercially available products and research applications, these antibodies perform effectively in:

• Western blot (WB): For detecting UPK2 protein expression levels

• Immunohistochemistry (IHC): Particularly valuable for bladder tissue specimens

• Immunocytochemistry (ICC): For cellular localization studies

• Immunofluorescence (IF): For high-resolution imaging of UPK2 distribution

• Enzyme-linked immunosorbent assay (ELISA): For quantitative protein measurements

• Flow cytometry (FCM): For analyzing UPK2 expression in cell populations

The selection of application should be guided by your experimental question, with immunohistochemistry being particularly valuable for tissue-specific studies of bladder pathology.

How can researchers generate recombinant mouse UPK2 protein for experimental purposes?

The generation of recombinant mouse UPK2 (rmUPK2) involves several methodological steps:

• RNA extraction from mouse bladder tissue using TRIzol reagent

• cDNA synthesis using random hexamers and M-MLV reverse transcriptase

• Subcloning of mouse UPK2 into an expression vector (e.g., pET 30b) using appropriate restriction enzymes (NcoI and HindIII)

• Transformation of the cloned vector into expression bacteria (BL21 DE3)

• Protein expression induction with isopropyl β-D-1-thiogalactopyranoside (1mM)

• Purification using nickel-column affinity chromatography under denaturing conditions

• Final purification using reverse-phase high-performance liquid chromatography to remove endotoxin

This methodological approach yields purified rmUPK2 that can be used for immunization, as standards in assays, or for other experimental applications requiring the target protein.

How can UPK2 antibodies be utilized to develop experimental autoimmune cystitis models?

UPK2 antibodies play a critical role in the development and characterization of experimental autoimmune cystitis (EAC) models, which serve as important tools for studying interstitial cystitis. The methodology involves:

• Immunization of mice (typically SWXJ female mice) with purified rmUPK2 protein (200 μg) mixed in complete Freund's adjuvant containing Mycobacteria tuberculosis H37RA

• Subcutaneous injection of the emulsion into the abdominal flank

• Evaluation of the immune response 5 weeks post-immunization

• Assessment of UPK2-specific T-cell responses in lymph nodes

• Measurement of serum antibody titers against rmUPK2

• Analysis of bladder inflammation and functional changes

This approach creates a bladder-specific autoimmune response that mimics many features of human interstitial cystitis, including increased urinary frequency and decreased void volume, making it valuable for studying disease mechanisms and potential therapeutic interventions.

What controls should be implemented when using UPK2 antibodies in experimental studies?

When designing experiments with UPK2 antibodies, implementing appropriate controls is essential:

• Positive tissue controls: Include known UPK2-expressing bladder tissues to validate antibody functionality

• Negative tissue controls: Include tissues known not to express UPK2 (e.g., liver, kidney) to confirm specificity

• Isotype controls: Use matched isotype control antibodies to assess non-specific binding

• Blocking peptide controls: Pre-incubate antibodies with UPK2 peptide to demonstrate binding specificity

• Multiple antibody validation: Confirm findings using different antibody clones targeting different UPK2 epitopes

For animal model studies specifically investigating autoimmune responses, control groups should include animals treated with adjuvant alone without the UPK2 protein to differentiate between specific immune responses and non-specific inflammation induced by the adjuvant .

What criteria should guide the selection of UPK2 antibodies for specific experimental applications?

When selecting UPK2 antibodies, researchers should consider:

• Application compatibility: Verify the antibody has been validated for your specific application (WB, IHC, IF, etc.)

• Species reactivity: Ensure the antibody recognizes UPK2 from your species of interest

• Clonality: Choose between polyclonal antibodies (broader epitope recognition) and monoclonal antibodies (higher specificity)

• Validated citations: Prioritize antibodies with published research citations

• Epitope location: Consider whether the target epitope is accessible in your experimental conditions

• Format requirements: Determine if unconjugated or conjugated formats are needed

Commercial suppliers offer approximately 91 different UPK2 antibodies across 18 suppliers , providing researchers with options tailored to specific experimental needs. The selection should be guided by the planned experimental approach and required specificity.

How can researchers validate the specificity of UPK2 antibodies?

Rigorous validation of UPK2 antibodies is crucial for experimental reliability. A comprehensive validation approach includes:

• Western blot analysis: Confirm a single band of appropriate molecular weight (approximately 19.4 kDa)

• Tissue panel screening: Test antibody reactivity across multiple tissues, expecting signal primarily in bladder tissue

• Peptide competition assays: Pre-incubate antibody with purified UPK2 protein to block specific binding

• Knockout/knockdown controls: Test antibody in UPK2 knockout tissues/cells or after siRNA knockdown

• Comparison with multiple antibodies: Validate findings using antibodies targeting different UPK2 epitopes

• Immunoprecipitation followed by mass spectrometry: Confirm the identity of the precipitated protein

Proper validation prevents misleading experimental results and ensures the antibody is truly detecting the intended UPK2 protein rather than cross-reacting with other proteins.

What are common challenges when using UPK2 antibodies in immunohistochemistry, and how can they be addressed?

Researchers frequently encounter several challenges when using UPK2 antibodies in immunohistochemistry:

These methodological adjustments can significantly improve the quality and reliability of UPK2 immunohistochemistry results.

How should researchers interpret contradictory results when using different UPK2 antibody clones?

When different UPK2 antibody clones yield contradictory results, a systematic approach to resolution includes:

• Epitope mapping: Identify the specific epitopes recognized by each antibody clone; differences may reflect isoform specificity or post-translational modifications

• Validation using multiple techniques: Compare results across different methods (e.g., WB, IHC, IF) to identify technique-specific issues

• Literature reconciliation: Review published studies using these specific antibody clones to identify known limitations

• Protein conformation considerations: Some epitopes may be masked in certain experimental conditions

• Positive and negative control validation: Re-validate all antibodies using well-characterized controls

• Functional validation: Consider functional assays that don't rely on antibody detection to confirm findings

Contradictory results often provide valuable insights into protein biology, potentially revealing different UPK2 forms, interactions, or modifications that vary under different conditions.

How are UPK2 antibodies being utilized in bladder cancer research?

UPK2 antibodies have become important tools in bladder cancer research across multiple applications:

• Diagnostic biomarker development: UPK2 expression analysis in urothelial carcinoma

• Circulating tumor cell detection: Identifying bladder cancer cells in blood samples

• Targeted therapy approaches: Developing UPK2-directed therapeutic approaches

• Cancer progression monitoring: Tracking changes in UPK2 expression during disease progression

• Tumor origin identification: Differentiating primary bladder tumors from metastases

The stable expression of UPK2 in human bladder cancer cell lines makes it a reliable target for ongoing cancer research , potentially leading to improved diagnostic and therapeutic approaches.

What is the current understanding of UPK2's role in interstitial cystitis pathogenesis?

Research using UPK2 antibodies has contributed significantly to our understanding of interstitial cystitis pathogenesis:

• Autoimmune mechanisms: Studies have demonstrated that immunization with rmUPK2 induces bladder-specific inflammation, suggesting autoimmunity against UPK2 may contribute to interstitial cystitis

• T-cell responses: UPK2-specific T-cell infiltration of bladder urothelium has been observed in experimental models

• Inflammatory mediators: Increased expression of inflammatory cytokines (TNF-α, IFN-γ, IL-17A, IL-1β) in bladder tissue following UPK2 immunization

• Functional changes: UPK2-induced autoimmunity leads to increased urinary frequency and decreased void volumes, mimicking human interstitial cystitis symptoms

• Tissue-specific effects: The inflammatory response appears confined to bladder tissue, without systemic autoimmune complications

These findings suggest autoimmunity against UPK2 may be a contributing factor in some cases of interstitial cystitis, providing potential new targets for therapeutic intervention.

What emerging applications of UPK2 antibodies show promise for bladder disease research?

Several emerging applications for UPK2 antibodies show significant promise:

• Single-cell analysis: Using UPK2 antibodies in single-cell proteomics to understand cellular heterogeneity in bladder disorders

• Liquid biopsy development: Detecting UPK2-positive exosomes or circulating tumor cells as non-invasive biomarkers

• Antibody-drug conjugates: Developing targeted therapies using UPK2 antibodies conjugated to therapeutic agents

• Spatial transcriptomics integration: Combining UPK2 protein localization with spatial gene expression analysis

• Bladder organoid validation: Using UPK2 as a marker to validate bladder organoid models

• Precision medicine approaches: Stratifying patients based on UPK2 expression patterns for personalized treatments

These applications represent the next frontier in utilizing UPK2 antibodies for both basic science and translational research in bladder pathologies.

How might improvements in UPK2 antibody technology enhance research capabilities?

Future technological advances in UPK2 antibody development could significantly enhance research capabilities:

• Increased specificity: Development of antibodies that distinguish between UPK2 isoforms or post-translational modifications

• Improved sensitivity: Next-generation antibodies with enhanced detection limits for low-abundance UPK2

• Multiparameter capabilities: Conjugated antibodies optimized for multiplex imaging or cytometry applications

• In vivo imaging applications: Development of non-immunogenic antibody fragments suitable for in vivo imaging

• Engineered antibody formats: Creation of bispecific antibodies targeting UPK2 alongside other bladder markers

• Recombinant antibody standardization: Shift toward recombinant antibodies for improved reproducibility

These technological improvements would address current limitations and expand the utility of UPK2 antibodies across the research landscape.